Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ibd/izad164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
alleviates experimentally acetic acid- induced ulcerative colitis in rats: targeting CB1/SIRT/MAPK signaling pathways.
Immunopharmacol Immunotoxicol
February 2025
Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Center, Cairo, Egypt.
Background: Ulcerative colitis (UC) is a frequent inflammatory bowel disease (IBD) that causes long-lasting inflammation in the innermost lining of the rectum and colon.
Objective: The aim of this study was to evaluate the therapeutic effect of () on the amelioration of acetic acid-induced colitis in rats.
Materials And Methods: Group 1: normal control group was intrarectally administered saline solution (0.
UK medical cannabis registry: an updated analysis of clinical outcomes of cannabis-based medicinal products for inflammatory bowel disease.
Expert Rev Gastroenterol Hepatol
December 2024
Medical Cannabis Research Group, Imperial College London, London, UK.
Background: Treatments for inflammatory bowel disease (IBD) remain limited, and cannabis-based medicinal products (CBMPs) provide promise in addressing inflammation and pain. However, long-term data on CBMP efficacy in IBD are scarce. This study examines health-related quality of life (HRQoL) changes in IBD patients treated with CBMPs.
View Article and Find Full Text PDFThe Potential of Cannabis in Managing Inflammatory Bowel Disease and Its Future Perspective.
Cureus
October 2024
Neurology, AINeuroCare Academy, Dallas, USA.
Inflammatory bowel disease (IBD) is an inflammation of the gastrointestinal tract mainly categorized as Crohn's disease and ulcerative colitis. The current management of IBD includes pharmacological, surgical, psychological, and complementary treatments, but cannabis effects are also becoming more popular as complementary therapies. Cannabinoids act on two G-protein coupled receptors, CB1 and CB2 located in the brain, enteric nervous system, gastrointestinal cells (epithelial cells), and immune cells.
View Article and Find Full Text PDFThe Modulatory Effects and Therapeutic Potential of Cannabidiol in the Gut.
Cells
September 2024
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292, USA.
Article Synopsis
- Cannabidiol (CBD) is a non-psychoactive compound from the cannabis plant that interacts with various receptors and has antioxidant properties.
- Research suggests that CBD has significant effects on the gastrointestinal (GI) system, influencing intestinal permeability, the microbiome, and immune responses, making it promising for treating GI disorders like inflammatory bowel disease (IBD).
- Future studies are essential to understand how CBD works in the gut and to conduct well-designed clinical trials to investigate its full therapeutic potential for both GI and non-GI related disorders.
Cannabinoids for Inflammatory Bowel Disease: A Scoping Review.
Cannabis Cannabinoid Res
July 2024
Colorectal Surgery, Royal Prince Alfred Hospital, Camperdown, Australia.
Inflammatory bowel disease (IBD) has two main variants, ulcerative colitis (UC) and Crohn's disease (CD), which are characterized by a cycle of remission and relapse. The aim of this scoping review is to understand the landscape of unprescribed and prescribed cannabis use among patients with IBD and investigate objective clinical benefits. A literature search was performed across Medline, Embase via Ovid, Scopus, and Cochrane Library databases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!